Fig. 6

Evaluation of NP ECM metabolism with the treatment of PCL, PCL/2% celecoxib nano fibers, and PCL/6% celecoxib nano fibers. a–h IHC of ACAN (a, b), Col2A1 (c, d), MMP3 (e, f), and MMP13 (g, h) in NP of rabbits treated with PCL, PCL/2% celecoxib nano fibers, and PCL/6% celecoxib nano fibers for 6 weeks and 12 weeks. *P < 0.05 compared with the puncture group, ^#P < 0.05 compared with the puncture + PCL celecoxib group, and ^†P < 0.05 compared with the puncture + PCL/2% celecoxib group